Investors Pour $55M Into Diabetes-Focused Biotech Fractyl
Fractyl Laboratories Inc., a life sciences company focused on developing treatments for metabolic diseases including Type 2 diabetes, said Friday that it has secured $55 million in funding from a group...To view the full article, register now.
Already a subscriber? Click here to view full article